The End May Be Near for Theranos & Elizabeth Holmes

Email not displaying correctly? View it in your browser.

June 26, 2018

		CONSUMER FRAUD The End May Be Near for Theranos & Elizabeth Holmes From - G2 Compliance Advisor Four years ago, Theranos was a $10 billion company poised to turn a breakthrough blood testing technology into a diagnostics dynamo to the tune of… Read More

		ACCREDITATION Top of the News: ANDE Rapid DNA Platform First to Win FBI Approval From - Laboratory Industry Report "Great news! The FBI just called." –Extremely rare phrase almost never uttered except sarcastically… Read More

		PRECISION MEDICINE Report Finds Genetic Tests and Their Reimbursement Increasingly Complex From - Diagnostic Testing & Emerging Technologies The health care technology company Concert Genetics (formerly NextGxDx; Nashville, Tenn.) recently released its third edition of… Read More

FEE SCHEDULES
How PAMA's Effect in 2018 Molecular Diagnostic Reimbursement Will Make Labs More Money
From - National Intelligence Report
The year 2018 is slated to be much brighter for molecular diagnostic labs as PAMA fee schedules show a higher payment rate and amount for many cancer genomics and…
Read More

For questions concerning delivery of this email, please contact customer service at:
(888) 729-2315 | customerservice@plainlanguagemedia.com